NBP · NovaBridge Biosciences
Market Cap
$150.80M
Shares
116.00M
Volume · Oct 20
431.02K
Avg daily vol (3M)
394.39K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.30
Open$1.27
Day$1.27–1.35
52W close$1.26–5.22
Avg vol 30d552K
Short int3.3M · 2.8% float · 3.5d
Short vol24%
Last earningsAug 20, 2026
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$75.48M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-11,395.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-31.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.0%
Year over year · more shares
Price change (1Y)
-77.5%
Trailing year
Short interest
2.8%
Latest settlement · 3.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
−20%
below
RSI (14)
34
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−46%
trailing
YTD return
−67%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +12 funds added
Insider flow
Distributing
Net -$88.3K over 90 days · 100% sells
Short interest
Falling
2.83% of float · ▼ -12.4% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
49 holders — mid 3-yr range
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
+141%
Y/Y
EPS growth
−75%
Y/Y
Free cash flow
$-183.8M
Buyback
$40.0M
authorized
Balance sheet
$210.6M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
34
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +12 funds added
Insider flow
Distributing
Net -$88.3K over 90 days · 100% sells
Short interest
Falling
2.83% of float · ▼ -12.4% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
49 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $5
vs 200-day avg -44%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NBP
this stock
NovaBridge Biosciences
|
$150.80M | -67.3% | +140.7% | — | 2.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NBP | -1.5% | -19.3% | -45.6% | -4.8% | -67.3% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | 0.0% | -18.3% | -53.3% | -5.3% | -79.7% |
Capital returns
Buyback program
· as of Dec 31, 2025
Authorized
$40.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.